Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Revance Therapeutics (NQ: RVNC ) 5.810 +0.010 (+0.17%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Revance Therapeutics < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday October 28, 2024 Via Benzinga “Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” October 28, 2024 Via AB Newswire Topics Artificial Intelligence Exposures Artificial Intelligence 12 Health Care Stocks Moving In Monday's Pre-Market Session October 28, 2024 Via Benzinga SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, ARC, K, RVNC on Behalf of Shareholders October 18, 2024 From Halper Sadeh LLC Via GlobeNewswire Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal August 12, 2024 Crown Laboratories will acquire Revance Therapeutics for $924 million, paying $6.66 per share — a premium of 89%. Via Benzinga SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, CPTN on Behalf of Shareholders October 17, 2024 From Halper Sadeh LLC Via GlobeNewswire The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors October 17, 2024 From The Law Offices of Frank R. Cruz Via Business Wire INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors October 15, 2024 From Law Offices of Howard G. Smith Via Business Wire Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors October 15, 2024 From Glancy Prongay & Murray LLP Via Business Wire SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, RVNC, ARC, RFL on Behalf of Shareholders September 27, 2024 From Halper Sadeh LLC Via GlobeNewswire REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC August 15, 2024 From Kahn Swick & Foti, LLC Via Business Wire SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, RVNC, BALY, DRQ on Behalf of Shareholders August 13, 2024 From Halper Sadeh LLC Via GlobeNewswire Gold Gains Over 1%; Starbucks Shares Move Higher August 12, 2024 Via Benzinga Why Is Revance Therapeutics (RVNC) Stock Up 86% Today? August 12, 2024 Revance Therapeutics stock is up on Monday as RVNC investors celebrate a $924 million merger agreement with Crown Laboratories. Via InvestorPlace Crude Oil Surges 2%; B. Riley Financial Shares Plunge August 12, 2024 Via Benzinga Exposures Fossil Fuels BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Revance Therapeutics, Inc. (Nasdaq – RVNC), Greenbrook TMS, Inc. (OTC – GBNHF), R1 RCM Inc. (Nasdaq - RCM), Enstar Group Limited (Nasdaq – ESGR) August 12, 2024 From Brodsky & Smith LLC Via GlobeNewswire KE Holdings, KeyCorp, Revance Therapeutics, Starbucks And Other Big Stocks Moving Higher On Monday August 12, 2024 Via Benzinga RVNC Investigation: Halper Sadeh LLC Is Investigating Whether the Sale of Revance Therapeutics, Inc. Is Fair to Shareholders August 12, 2024 From Halper Sadeh LLC Via Business Wire Dow Dips 150 Points; Monday.com Posts Upbeat Earnings August 12, 2024 Via Benzinga Topics Stocks Exposures US Equities RVNC Stock Earnings: Revance Therapeutics Beats EPS, Misses Revenue for Q2 2024 August 08, 2024 RVNC stock results show that Revance Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. Via InvestorPlace Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update August 08, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024 August 01, 2024 From Revance Therapeutics, Inc. Via Business Wire AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now? July 22, 2024 The big pharma company's top drug is losing ground, but its dividend keeps rising. Via The Motley Fool Stocks to Buy: 3 Breakout Stars to Transform Your Portfolio July 11, 2024 Although breakout stocks present high risks, the underlying lack of predictability provides fuel for tremendous upside. Via InvestorPlace Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 14, 2024 From Revance Therapeutics, Inc. Via Business Wire Revance to Participate in Upcoming Investor Conferences May 28, 2024 From Revance Therapeutics, Inc. Via Business Wire The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains May 22, 2024 Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them. Via InvestorPlace 3 Underappreciated Stocks That Could 10x in 10 Years May 12, 2024 10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line. Via InvestorPlace 12 Health Care Stocks Moving In Friday's Intraday Session May 10, 2024 Via Benzinga Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session May 10, 2024 Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 14 15 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
